Serum copper level in non-Hodgkin's lymphomas

Area of Science:

• Oncology
• Clinical Chemistry

Background:

• Non-Hodgkin's lymphoma (NHL) is a heterogeneous group of lymphoid malignancies.
• Identifying reliable biomarkers for disease activity and prognosis in NHL is crucial for effective patient management.

Purpose of the Study:

• To investigate the correlation between serum copper levels (SCL) and disease status in patients with non-Hodgkin's lymphoma.
• To evaluate SCL as a potential prognostic index for treatment response and survival in NHL.

Main Methods:

• Atomic absorption spectroscopy was used to measure SCL in 103 NHL patients.
• SCL was analyzed in relation to disease activity (active disease vs. complete remission), clinical stage, and histologic type.
• Statistical analysis was performed to assess the significance of SCL variations and their association with treatment outcomes and survival.

Main Results:

• Elevated SCL was observed in 61% of patients with active disease, while 88% of patients in complete remission had normal SCL.
• High SCL at diagnosis was significantly associated with poorer treatment response in stages II and III NHL.
• High SCL at diagnosis correlated with shorter 5-year survival in stages III and IV NHL, particularly in poorly differentiated lymphocytic lymphoma.

Conclusions:

• Serum copper level serves as a valuable indicator of disease activity in non-Hodgkin's lymphoma.
• SCL is a useful prognostic index for predicting treatment response and survival outcomes in NHL patients.
• Monitoring SCL may aid in clinical decision-making and patient management strategies for NHL.